RxDoctor Payments Data

Orin Douglas, MD

Family Medicine · New York, NYNPI 1487810636

Payments from drug & device makers

$24,602in general payments, 2019–2025

Across 765 payments — averaging $32.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$9K
  • Gilead$4K
  • Johnson & Johnson$3K
  • Janssen Products, LP$3K
  • Janssen Scientific Affairs, LLC$2K
  • Theratechnologies Inc.$1K
  • plus $2K from 13 others

What the payments were for

  • Consulting fees$4,66519%
  • Travel & lodging$590%
  • Food & beverage$18,89877%
  • Education$9804%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,602 in reported general payments places this provider in the 95th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$6,212
Medicare patients
11
Services billed
110

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala84$328,437
DovatoDolutegravir Sodium/Lamivudine37$105,788
JulucaDolutegravir/Rilpivirine27$91,284
Egrifta SvTesamorelin Acetate12$77,861
TivicayDolutegravir Sodium21$45,019
PrezcobixDarunavir/Cobicistat12$30,119
JardianceEmpagliflozin40$23,797
OzempicSemaglutide18$16,789
VascepaIcosapent Ethyl20$6,939
Testosterone21$2,392
Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf)17$1,247
Pitavastatin Calcium12$817
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$664
Eplerenone13$553
ValacyclovirValacyclovir Hcl25$435

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$4,258$328,43784 claims
Viiv Healthcare CompanyDovato, Juluca, Tivicay$8,694$242,09285 claims
Theratechnologies Inc.Egrifta Sv$1,344$77,86112 claims
Johnson & JohnsonPrezcobix$2,970$30,11912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,321 family medicine providers in New York.

Other family medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →